High-precision targeting and destruction of cancer-associated PDGFR-β+ stromal fibroblasts through self-assembling, protein-only nanoparticles
Source abstract
Abstract
The need for more effective and precision medicines for cancer has pushed the exploration of new materials appropriate for drug delivery and imaging, and alternative receptors for targeting. Among the most promising strategies, finding suitable cell surface receptors and targeting agents for cancer-associated platelet derived growth factor receptor β (PDGFR-β)+ stromal fibroblasts is highly appealing. As a neglected target, this cell type mechanically and biologically supports the growth, progression, and infiltration of solid tumors in non-small cell lung, breast, pancreatic, and colorectal cancers. We have developed a family of PDGFR-β-targeted nanoparticles based on biofabricated, self-assembling proteins, upon hierarchical and iterative selective processes starting from four initial candidates. The modular protein PDGFD-GFP-H6 is well produced in recombinant bacteria, resulting in structurally robust oligomeric particles that selectively penetrates into PDGFR-β+ stromal fibroblasts in a dose-dependent manner, by means of the PDGFR-β ligand PDGFD. Upon in vivo administration, these GFP-carrying protein nanoparticles precisely accumulate in tumor tissues and enlighten them for IVIS observation. When GFP is replaced by a microbial toxin, selective tumor tissue destruction is observed associated with a significant reduction in tumor volume growth. The presented data validate the PDGFR-β/PDGFD pair as a promising toolbox for targeted drug delivery in the tumor microenvironment and oligomeric protein nanoparticles as a powerful instrument to mediate highly selective biosafe targeting in cancer through non-cancer cells. We have developed a transversal platform for nanoparticle-based drug delivery into cancer-associated fibroblasts. This is based on the engineered modular protein PDGFD-GFP-H6 that spontaneous self-assemble and selectively penetrates into PDGFR-β+ stromal fibroblasts in a dose-dependent manner, by means of the PDGFR-β ligand PDGFD. In vivo, these protein nanoparticles accumulate in tumor and when incorporating a microbial toxin, they destroy tumor tissues with a significant reduction in tumor volume, in absence of side toxicities. The data presented here validate the PDGFR-β/PDGFD pair as a fully versatile toolbox for targeted drug delivery in the tumor microenvironment intended as a synergistic treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Why is cancer drug discovery so difficult?10.1038/nrd2155 ↗
3. Targeting glycosylation: a new road for cancer drug discovery10.1016/j.trecan.2020.04.002 ↗
4. Targeting apoptosis in cancer therapy10.1038/s41571-020-0341-y ↗
5. Cancer gene therapy: fringe or cutting edge?10.1038/35101008 ↗
6. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery10.1038/nrd2137 ↗
7. Protein-driven nanomedicines in oncotherapy10.1016/j.coph.2018.12.004 ↗
8. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
9. Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy10.1016/j.semcancer.2019.11.002 ↗
10. Nanoparticle-delivered chemotherapy: old drugs in new packages
11. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment10.1016/j.addr.2017.05.006 ↗
12. Cancer nanomedicine: progress, challenges and opportunities10.1038/nrc.2016.108 ↗
13. Cancer nanomedicine: a review of recent success in drug delivery10.1186/s40169-017-0175-0 ↗
14. Targeted nanotechnologies for cancer intervention: a patent review (2010-2016)10.1080/13543776.2017.1344216 ↗
15. Biparatopic protein nanoparticles for the precision therapy of CXCR4+ cancers10.3390/cancers13122929 ↗
16. Principles in the design of ligand-targeted cancer therapeutics and imaging agents10.1038/nrd4519 ↗
17. Multivalency in drug delivery–when is it too much of a good thing?10.1021/acs.bioconjchem.8b00804 ↗
18. Formulating tumor-homing peptides as regular nanoparticles enhances receptor-mediated cell penetrability10.1016/j.matlet.2015.04.055 ↗
19. Multimeric RGD-based strategies for selective drug delivery to tumor tissues10.3390/pharmaceutics15020525 ↗
20. Multivalent interactions: synthesis and evaluation of melanotropin multimers–tools for melanoma targeting10.1021/ml300312b ↗
21. Nanomedicine(s) under the microscope10.1021/mp200394t ↗
22. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
23. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
24. Toxicology and clinical potential of nanoparticles10.1016/j.nantod.2011.10.001 ↗
25. Cytotoxicity of Nanoparticles10.1002/smll.200700595 ↗
26. In vivo architectonic stability of fully de novo designed protein-only nanoparticles10.1021/nn4055732 ↗
27. Selective depletion of metastatic stem cells as therapy for human colorectal cancer10.15252/emmm.201708772 ↗
28. Intracellular CXCR4+ cell targeting with T22-empowered protein-only nanoparticles
29. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models10.3324/haematol.2018.211490 ↗
30. Novel endometrial cancer models using sensitive metastasis tracing for CXCR4-targeted therapy in advanced disease10.3390/biomedicines10071680 ↗
31. Protein-based therapeutic killing for cancer therapies10.1016/j.tibtech.2017.11.007 ↗
32. Cancer associated fibroblasts: the architects of stroma remodeling10.1002/pmic.201700167 ↗
33. The tumor microenvironment innately modulates cancer progression10.1158/0008-5472.CAN-18-3962 ↗
34. The biology and function of fibroblasts in cancer10.1038/nrc.2016.73 ↗
35. PDGFR-beta(+) fibroblasts deteriorate survival in human solid tumors: a meta-analysis10.18632/aging.202952 ↗
36. The role of cancer-associated fibroblasts in cancer invasion and metastasis10.3390/cancers13184720 ↗
37. Platelet‑derived growth factor receptor‑β gene expression relates to recurrence in colorectal cancer
38. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells10.1593/neo.121726 ↗
39. The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast10.1016/j.critrevonc.2018.08.002 ↗
40. Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients10.18632/oncotarget.18415 ↗
41. Platelet-derived growth factor receptor alpha (PDGFRα) is overexpressed in NK/T-cell lymphoma and mediates cell survival10.1016/j.bbrc.2018.08.181 ↗
42. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence10.1038/srep43378 ↗
43. The expression of Platelet-derived Growth factor receptors (PDGFRs) and their correlation with overall survival of patients with ovarian cancer10.5603/GP.a2019.0045 ↗
44. PDGF receptors in tumor stroma: biological effects and associations with prognosis and response to treatment10.1016/j.addr.2017.09.022 ↗
45. Targeting the tumour stroma to improve cancer therapy10.1038/s41571-018-0007-1 ↗
46. Development of radiogallium-labeled peptides for platelet-derived growth factor receptor β (PDGFRβ) imaging: influence of different linkers10.3390/molecules26010041 ↗
47. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism10.1016/j.toxlet.2018.05.033 ↗
48. The PDGF/PDGFR pathway as a drug target10.1016/j.mam.2017.11.007 ↗
49. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery10.1016/j.jconrel.2022.01.017 ↗
50. Insights on the emerging biotechnology of histidine-rich peptides10.1016/j.biotechadv.2021.107817 ↗
51. An in silico methodology that facilitates decision making in the engineering of nanoscale protein Materials10.3390/ijms23094958 ↗
52. Designed and biologically active protein lattices10.1038/s41467-021-23966-4 ↗
53. Insights on the emerging biotechnology of histidine-rich peptides10.1016/j.biotechadv.2021.107817 ↗
54. Biofabrication of functional protein nanoparticles through simple His-tag engineering10.1021/acssuschemeng.1c04256 ↗
55. Strategies for fabricating protein films for biomaterial applications10.1002/adsu.202000167 ↗
56. Building protein networks in synthetic systems from the bottom-up10.1016/j.biotechadv.2021.107753 ↗
57. Highly ordered protein cage assemblies: a toolkit for new materials10.1002/wnan.1578 ↗
58. Order/disorder in protein and peptide-based biomaterials10.1002/ijch.201900051 ↗
59. Recent progress in designing protein-based supramolecular assemblies10.1016/j.sbi.2020.05.001 ↗
60. Natural protein bioinspired materials for regeneration of hard tissues10.1039/D0TB00139B ↗
61. Differential tumorigenic potential and matriptase activation between PDGF B versus PDGF D in prostate cancer10.1158/1541-7786.MCR-12-0071 ↗
62. Peptide-based targeting of the platelet-derived growth factor receptor beta10.1007/s11307-012-0578-7 ↗
63. Imaging of platelet-derived growth factor receptor beta expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z0959110.2967/jnumed.113.121814 ↗
64. Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo10.1021/mp500284t ↗
65. Engineering protein nanoparticles out from components of the human microbiome10.1002/smll.202001885 ↗
66. Pre-expression of a sulfhydryl oxidase significantly increases the yields of eukaryotic disulfide bond containing proteins expressed in the cytoplasm of E.coli10.1186/1475-2859-10-1 ↗
67. Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase10.1016/j.pep.2011.03.005 ↗
68. Enabling IMAC purification of low abundance recombinant proteins from E. coli lysates10.1038/nmeth0709-477 ↗
69. Controlling self-assembling and tumor cell-targeting of protein-only nanoparticles through modular protein engineering10.1007/s40843-019-9582-9 ↗
70. Highly accurate protein structure prediction with AlphaFold10.1038/s41586-021-03819-2 ↗
71. UCSF ChimeraX: structure visualization for researchers, educators, and developers10.1002/pro.3943 ↗
72. Snail1 controls TGF-β responsiveness and differentiation of mesenchymal stem cells10.1038/onc.2012.342 ↗
73. Snail1-dependent activation of cancer-associated fibroblast controls epithelial tumor cell invasion and metastasis10.1158/0008-5472.CAN-16-0176 ↗
74. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene10.1158/0008-5472.CAN-04-4510 ↗
75. Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts10.1038/bjc.1993.453 ↗
76. A mouse model to investigate the role of cancer-associated fibroblasts in tumor growth
77. Protumorigenic effects of Snail-expression fibroblasts on colon cancer cells10.1002/ijc.28613 ↗
78. Divalent cations: a molecular glue for protein materials10.1016/j.tibs.2020.08.003 ↗
79. Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles10.1016/j.biomaterials.2012.08.033 ↗
80. The spectrum of building block conformers sustains the biophysical properties of clinically-oriented self-assembling protein nanoparticles10.1007/s40843-021-1914-0 ↗
81. Bottom-up instructive quality control in the biofabrication of smart protein materials10.1002/adma.201503676 ↗
82. Nanostructure empowers active tumor targeting in ligand-based molecular delivery10.1002/ppsc.201900304 ↗
83. T22-PE24-H6 nanotoxin selectively kills CXCR4-high expressing AML patient cells in vitro and potently blocks dissemination in vivo10.3390/pharmaceutics15030727 ↗
84. A self-assembling CXCR4-targeted pyroptosis nanotoxin for melanoma therapy10.1039/D2BM02026B ↗
85. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations10.1007/s00280-019-03875-6 ↗
86. Size-dependent endocytosis of nanoparticles10.1002/adma.200801393 ↗
87. Effects of particle size and ligand density on the kinetics of receptor-mediated endocytosis of nanoparticles10.1063/1.3293303 ↗
88. Banerjee A., Berzhkovskii A., Nossal R. Efficiency of cellular uptake of nanoparticles via receptor-mediated endocytosis. arXiv preprint arXiv:14117348 2014.
89. Strategies to improve the EPR effect: a mechanistic perspective and clinical translation10.1016/j.jconrel.2022.03.043 ↗
90. Towards protein-based viral mimetics for cancer therapies10.1016/j.tibtech.2015.02.007 ↗
91. Dual-receptor targeted strategy in nanoparticle design achieves tumor cell selectivity through cooperativity10.1039/C8NR09431D ↗
92. Ligand-binding cooperativity effects in polymer-protein conjugation10.1021/acs.biomac.9b00016 ↗
93. Cooperativity principles in self-assembled nanomedicine10.1021/acs.chemrev.8b00195 ↗
94. Recent advances in "smart" delivery systems for extended drug release in cancer therapy10.2147/IJN.S168053 ↗
95. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours10.1016/j.jconrel.2019.11.014 ↗
96. Protein based nanostructures for drug delivery
97. Engineered nanoparticles interacting with cells: size matters10.1186/1477-3155-12-5 ↗
98. CXCR4-targeted nanotoxins induce GSDME-dependent pyroptosis in head and neck squamous cell carcinoma
99. Specific cytotoxic effect of an auristatin nanoconjugate towards CXCR4(+) diffuse large B-cell lymphoma Cells10.2147/IJN.S289733 ↗
100. Design and engineering of tumor-targeted, dual-acting cytotoxic nanoparticles10.1016/j.actbio.2020.11.018 ↗